(Sharecast News) - Avacta Therapeutics said on Wednesday that it has received clearance from the US Food and Drug Administration for the investigational new drug application for 'FAP-Exatecan', or AVA6103, marking the transition of its second 'preCISION' medicine from preclinical development into human trials.
The AIM-traded biopharmaceutical company said the clearance...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE